PD-1 will be a new drug to invest in Waterloo! There are also targets that are repeating the PD-1 mistake involving 15 companies

"There is an old saying in China that there is a rush to invest in medicine, and now there is a rush of money to invest.
, a member of the Science and Technology Innovation Advisory Committee and chairman of the Asian Cancer Alliance, said.
at the 3rd Health Industry Investment and Financing Leaders Summit, Li Jin delivered a speech entitled "Rational Investment in Anti-Tumor Innovative Drug Research and Development".
In the field of anti-tumor drug research and development, Li Jin shared four ways to invest: one is to invest in projects, such as PD-1 mono-resistance, called special investment; Name, and then set up a team to go to sea, called team investment; the third is enterprise investment, this enterprise may be about to go public, forming a certain scale, this time to invest in enterprises to do products, this is called enterprise investment; the fourth is the secondary market.
01 PD-1 monoantitor will be the future of innovative drug investment waterloo as of September this year, in the field of anti-tumor, CDE has approved nearly 20 new adaptive disorders, the industry has reached a climax.
"We have a historic opportunity, but what is innovation?" Everyone is saying he's innovative, but not necessarily.
" Li Jin asked himself, in this environment, how to make investment decisions? What drugs are innovative? "Is PD-1 innovative?" Can you say it's not innovative? An estimated 126 companies in China now have PD-1 or PDL-1 products, all innovative because they all have international patents.
"but this is not innovation, Li Jin believes, "PD-1 single resistance can become the future of innovative pharmaceutical investment in Waterloo, why?" "In 2019, China's first PD-1 went on sale at a cost of about 200,000 yuan a year.
, Thyda Bio's Xindili single-resistance listing, into the health insurance a year no more than 100,000 yuan, less than a year the value of the decline of half, of course, it can still be profitable.
the PD-1 market has been surging this year as health-care negotiations have moved quickly.
according to E drug manager statistics, the new round of health care negotiations in 2020 catalog, in addition to the already into the health insurance of the Xindili single resistance, 7 PD-(L)1 products have all gathered, ready to go.
October 25, Hengrui Pharmaceuticals announced that it would lower its PD-1 Karelli Pearl single resistance price to 30,000 yuan/year.
price reduction before the hemnray talks, no doubt gave the whole market a layer of fire oil.
" to do a PD-1, investment of about 10-2 billion, if a year only 30,000 yuan price, how to maintain? How do you make a profit? If you use blades as thin as profits, how can you drive innovative pharmaceuticals? Li Jin threw out a question.
" now approved in the development, clinical PD-1 single resistance a total of 62, in another five years, we estimate that there will be about 80 enterprises have PD-1, PD-L1, then not for everyone injections, is PD-(L)1 for everyone to bathe.
, " Li Jin humorously described.
for the investment community, the commercialization of PD-1 in China is actually the first test field to test the results of investment in new drugs.
02 CLDN18.2 targets are repeating the same PD-1 single resistance " We are still repeating the mistakes of PD-1, Claudin 18.2 (CLDN18.2), the largest development in China, a total of 15, only 2 in the United States.
" Li Jin said.
CLDN18.2 protein is by far the most thoroughly studied Claudin family protein.
The abnormal expression of Claudins can lead to structural damage and functional damage of endosthal cells, which are abnormally expressed in tumors from a variety of endoscape sources, indicating that Claudins may play an important role in tumor invasion and metastasis.
hypothesis is that in tumor metabolism, the reduction in Claudins expression levels enhances tumor metastasis and invasion.
the target in the stomach cancer and pancreatic cancer two types of cancer expression upward, so the current target of CLDN18.2 target research is mostly stomach cancer.
research and development of the target, seven companies worldwide that currently have patents for the target drug are in clinical trials.
, Astellas is at the fore, with IMAB362 being the first chic monoantial to target CLDN18.2, adapted to stomach cancer, and is currently in clinical phase 3.
AMG910 is a dual-specific antibody drug targeting CD3 and CLDN18.2, which is adapted to prove stomach cancer and gastroesophageal junction adenocarcinoma and is currently in clinical phase 1.
the product was approved by the CDE on July 1st.
domestic aspects, Koji Bio's AB011 is the first single resistance for CLDN18.2 independent research and development in China, and the first humanized single resistance for this target in the world, which is currently in clinical phase 1.
addition, Osaikang, Maybos Bio, Genesis Group are in clinical phase 1, and many more are in the preclinical stage.
" so-called innovation may not necessarily be innovation, the real innovation is not whether there are patents, but whether the industry first.
," Li Jin warned.
" in fact, in the process of review and approval is also doing innovation.
" Li Jin continues to give examples, "similar products must be effective in order to be approved, so now many PD-1 single-resistance research and development manufacturers are anxious, why? If lung cancer has PD-1 adaptation, and then want to take this allergy, you must take this drug as a control, and head-to-head control.
"03 Biopharmaceutical investment must embrace the group heating China is currently the world's investment hot spot, especially after the new crown epidemic, the speed of China's economic development has attracted the attention of the world's investment industry.
", so China will be the biggest investment fertile ground in the future, when the world's big crocodiles come to China, to see where the big capital to invest, you follow the investment.
," Li Jin thinks.
" global TNC development scale and model are different.
Roche has never had its own research and development team, it's all buy-to-let, Pfizer is selling, and Novart, and all of its products are sold to others for development.
there are some companies like Lilly that are cooperative and local.
," Li Jin said.
" Lilly in China to invest in 2 enterprises, it is a cooperative type, if it casts, you follow, why? Because it has a BD team, to do the tune, a tune can be adjusted for two years, must be 99.9% can be successful, so this time it to where to cast, you bravely to where to cast, absolutely no mistake, we call it a big money.
" to give you two examples, Baiji Shenzhou and Anjin cooperation, as well as Xinda and Lilly's cooperation, this is the group heating.
" later I found more than this, because the fund investment is all hugging group heating, very few funds say a investment, about only 10% to 20%, most of them are together to engage in two hundred million, three hundred million.
" bio-industry investment risk is particularly large, non-white or black.
", the investment biopharmaceutical industry must embrace the group heating.
if you split the money into ten, twenty, and put in one or two dozen clinical drugs, the chances of success are basically 20 to 30 percent, " he said.
if you only vote for one project and all fail, that's why you have to hold the group to keep warm, " he said.
"" Who put a drug on the market? Li Jin suddenly asked 380 investors.
surprised, only three people raised their hands.
, however, is the embarrassment that new drug investments are experiencing.
2019, the Chinese Academy of Engineering conducted an international comparative analysis of 26 representative manufacturing industries, which showed that China's manufacturing industry as a whole is still at the low end of the global value chain, with biopharmaceuticalsin the list.
Li Jin also suggested that investors should look at listing rationally, IPO is not the ultimate goal.
not to see money in their eyes, to have a sense of mission, to the clinical value of new drugs and the clinical needs of patients in the first place.
" for example, I'm talking about anti-tumor drugs, can you let the patient live longer, originally only live one year, the result of your investment, you produce drugs after let him live two more years.
"04 The future direction of investment in new drugs? Hormones were used to treat tumors in 1941, the first anti-cancer drugs came out in 1957, and now thousands of drugs are on the market, with little presence in China.
" but from 2017 to now, in just three years there are five innovative drugs on the market, in the future we want to have China's Huawei Pharmaceuticals, to have China's TOP pharmaceutical companies, to enter the world's top industry.
"Li Jin put forward so much hope.
achieve these goals without capital.
the first half of 2020, the number of clinical trials in China has surpassed that of the United States, ranking first in the world, according to CoreLogic.
such an innovative trend, how to choose the future direction of investment in new drugs has become a compulsory course.
li believes there are three directions worth investing in: the first is a new target.
of the more than 400 available targets, there are targets unique to Chinese companies that are not available all over the world, " he said.
thinks money can be put into universities and into Chinese university professors.
a second dual-function single resistance.
" is the original single-function antibody, this target antibody is often '1-plus-one-gt;3', do not be confused eyes, theory that any two targets can be made into a dual-functional monoantigen, but this dual-functional mono-resistance can not exceed the effect of two mono-resistance, 1-1 is not really greater than 3, really greater than 3 on the brave cast, dual-functional mono-resistance is the focus of the future biopharmaceutical industry.
" third cell therapy technique.
" In fact, we used to do cell therapy 20 years ago, the original NK cells, we are now entering a new era of CAR, the traditional NK will be assigned a new mission, the new CAR NK listed, because this toxicity is too great, and CAR NK circumvented CAR toxicity.
addition, two cell therapists, we lead the way in technology and one is TIL technology, which could be the way forward.
"